Full-Time

Senior Director

Assistant General Counsel, Patent Attorney

Posted on 5/18/2025

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

10,001+ employees

Develops biopharmaceuticals for serious diseases

Compensation Overview

$238.4k - $397.3k/yr

Senior, Expert

Tarrytown, NY, USA

In Person

This role requires 4 days per week onsite at our Global HQ Campus in Tarrytown, NY. This is not available as a fully remote / hybrid work.

Category
Intellectual Property (IP)
Legal & Compliance
Requirements
  • Ph.D. in life sciences (e.g., molecular biology, genetics, cell biology, immunology, neuroscience) with significant research experience
  • Juris Doctorate from an accredited law school
  • Admitted to practice before the USPTO
  • Licensed to practice law in at least one state (preferably NY)
  • At least 8-10 years of experience in biotechnology patent law in a law firm or corporate law department
  • Minimum 5 years of experience in patent application preparation and prosecution in the biological arts in a law firm setting
Responsibilities
  • Identify and capture new inventions in CRISPR/Cas genome engineering, anti-sense, antibody-targeted therapeutics, and recombineering technologies
  • Prepare and manage global patent portfolios for genetic medicines technology platforms
  • Oversee outside counsel on various projects
  • Conduct patent landscape, freedom-to-operate, validity, and patentability assessments for Regeneron’s genetic medicines and report findings to senior management
  • Manage US and foreign administrative patent actions (e.g., post-grant oppositions, third-party submissions, inter partes reviews)
  • Assist in litigation activities as needed
  • Support due diligence projects, agreements, transactional work, administrative initiatives, and policy questions
Desired Qualifications
  • A progressive career collaborating with top-tier scientists and business units to coordinate patent filings, protect trade secrets, and handle administrative patent actions, including post-grant oppositions in Europe
  • Significant experience advising on emerging legal issues, staying updated on case law and legislative changes, and contributing to projects that uphold the highest legal and ethical standards
  • Strong organizational skills and ability to manage multiple projects and competing priorities
  • Ability to handle a large and complex docket with minimal supervision
  • Exceptional communication skills, including presentation, interpersonal, writing, and conflict resolution
Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

View

Regeneron Pharmaceuticals develops medicines aimed at treating serious diseases such as cancer, eye diseases, and allergic conditions. The company uses its own technologies and extensive research to create new therapies, often collaborating with academic institutions and other pharmaceutical companies to enhance its efforts. Regeneron generates revenue by selling its approved medicines and through licensing agreements, sharing costs and profits with partners. Its clients include healthcare providers and hospitals, and the company works closely with regulatory agencies to ensure safety and efficacy of its products. Regeneron's goal is to improve patient outcomes through effective treatments.

Company Size

10,001+

Company Stage

IPO

Headquarters

Town of Greenburgh, New York

Founded

1988

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of 23andMe assets boosts consumer genomics and drug discovery capabilities.
  • Dupixent's success in respiratory treatments strengthens market position.
  • Strategic partnerships integrate advanced technologies into treatment solutions.

What critics are saying

  • Integration challenges with 23andMe's consumer-focused business model.
  • Failure of AERIFY-2 study may impact investor confidence.
  • Intensifying competition in biologics market could affect Dupixent's market share.

What makes Regeneron Pharmaceuticals unique

  • Regeneron excels in developing life-transforming medicines for serious diseases.
  • The company leverages proprietary technologies for innovative drug discovery.
  • Regeneron collaborates with academic and research institutions to enhance R&D efforts.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Wellness Program

Paid Vacation

Equity Awards

Annual Bonuses

Flexible Work Hours

Company News

PharmaData
Jun 25th, 2025
Regeneron Launches Innovative Donation Matching Initiative in Partnership with Independent Patient Assistance Charity

Regeneron launches innovative donation matching initiative in partnership with independent patient assistance charity.

PharmiWeb
Jun 16th, 2025
Eaaci: Dupixent Demonstrated Superiority Over Xolair (Omalizumab) In Chronic Rhinosinusitis With Nasal Polyps In Patients With Coexisting Asthma In First-Ever Presented Phase 4 Head-To-Head Respiratory Study

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpointsDupixent also outperformed Xolair in improving such key signs and symptoms as nasal polyp size and sense of smell in CRSwNP, and lung function and disease control in asthma, with rapid improvements seen as early as 4 weeksResults reinforce the efficacy of Dupixent in treating both upper and lower respiratory diseases by targeting IL-4 and IL-13, two key drivers of type 2 inflammation Paris and Tarrytown, NY, June 15, 2025. Sanofi and Regeneron Pharmaceuticals, Inc. today presented positive results from the EVEREST phase 4 study of adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP) and coexisting asthma. In the study, Dupixent (dupilumab) outperformed Xolair (omalizumab) on all primary and secondary efficacy endpoints of CRSwNP, and in all asthma-related endpoints. The data are from the first-ever presented head-to-head respiratory study with biologic medicines and were shared today in a late-breaking oral presentation at the 2025 European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress, Glasgow, UK. Eugenio De Corso, MD, PhD ENT Specialist, Otolaryngology, Head and Neck Surgery, Rhinology, A

PharmiWeb
Jun 2nd, 2025
Itepekimab Met The Primary Endpoint In One Of Two Copd Phase 3 Studies

Itepekimab met the primary endpoint in one of two COPD phase 3 studies. AERIFY-1 study met its primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a clinically meaningful benefit. AERIFY-2 study, a second Phase 3 study, did not meet the primary endpoint despite a benefit seen earlier in the study

MarketBeat
Jun 1st, 2025
Summit Global Investments Invests $849,000 in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Regeneron Pharmaceuticals Inc. purchased a new stake in Alnylam Pharmaceuticals in the 4th quarter worth approximately $1,045,822,000.

CNBC
May 27th, 2025
23Andme To Delist From Nasdaq, Deregister With Sec

A sign is posted in front of the 23andMe headquarters in Sunnyvale, California, on Feb. 1, 2024.Justin Sullivan | Getty Images23andMe on Tuesday announced it will voluntarily delist from the Nasdaq and de-register with the U.S. Securities and Exchange Commission, according to a release. The move comes after Regeneron Pharmaceuticals said earlier this month that it will acquire "substantially all" of 23andMe's assets for $256 million. The drugmaker came out on top following a bankruptcy auction for 23andMe, a once high-flying genetic testing company that filed for for Chapter 11 bankruptcy protection in March.This is breaking news. Please refresh for updates

INACTIVE